Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gastrointestinal 50Head & Neck 24Breast 22Thoracic 21CNS 19Sarcoma 18Genitourinary 12Dermatologic 8Gynecologic 6Tumor-Agnostic 4Endocrine 2Classical hematology 1

Conditions

Pituitary Neoplasms 1Insulinoma 1Acromegaly 1

Interventions

lutetium Lu 177 dotatate 31Magnetic Resonance Spectroscopy 25pembrolizumab 21Specimen Handling 18Nivolumab 17cabozantinib 14lenvatinib 12Everolimus 12trametinib 11gallium Ga 68 dotatate 10dabrafenib 10Ipilimumab 10Carboplatin 10Cisplatin 8atezolizumab 7Temozolomide 7Lutetium-177 7Capecitabine 7X-Rays 6Etoposide 6surufatinib 5olaparib 5lanreotide 5fluorodopa F 18 5cemiplimab 5Vemurafenib 5Paclitaxel 5Octreotide 5Lutetium 5Fluorodeoxyglucose F18 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Surgical Procedures, Operative × Endocrine × 1 year × Clear all
NCT05735912 2026-01-13

ERASIN-RCT

Azienda Ospedaliera Universitaria Integrata Verona

Phase NA Active not recruiting
60 enrolled
Endocrine

Insulinoma

NCT01809808 2025-08-26

A Prospective Study of Outcome After Therapy for Acromegaly

Columbia University

Completed
280 enrolled
Endocrine

Acromegaly, Pituitary Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡